News
The new approval will help Merck make a return on its $3.9 billion investment in acquiring SpringWorks, which has operated as ...
LLY's explosive growth from Mounjaro and Zepbound outpaces MRK's Keytruda-led gains, despite valuation concerns.
In June 2025, the FDA approved KEYTRUDA for perioperative use in adults with resectable, locally advanced head and neck ...
Michelle Xia gained experience at U.S. pharmaceutical firms before launching her own biotech company back home in China. In a ...
On July 9, Merck announced that it would acquire Verona Pharma, a U.K.-based biotechnology company specializing in the ...
12h
Stocktwits on MSNMerck’s Blockbuster Drug Keytruda Gets Canadian Regulator’s Approval For Treating Cervical Cancer: Retail Investors Appear DividedMerck (MRK) announced on Monday that the Canadian regulator, Health Canada, has granted approval for its cancer drug Keytruda ...
Merck said on Wednesday it will acquire UK-based Verona Pharma for about $10 billion, gaining a promising respiratory ...
The new drug application is supported by 48-week data from the Phase III MK-8591A-051 and MK-8591A-052 trials, which showed ...
A key patent for Merck’s blockbuster drug Keytruda will expire in 2028. The cancer therapy brought the company $29.5 billion ...
Merck aims to boost its business by buying Verona Pharma for $10 billion. Through the deal, it will add Ohtuvayre -- a ...
The New Jersey-based pharma has inked one of the biggest deals of the year in pursuit of a promising new way to treat COPD.
Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results